drug combination
199 articles
AACR Annual Meeting 2021 Highlights
Let’s Win and the Lustgarten Foundation bring you the pancreatic cancer research highlights of the 2021 AACR Annual Meeting,
RNA Precision Trial for Pancreatic Cancer Opens At Columbia
Dr. Andrea Califano leads a precision oncology clinical trial of the OncoTreat platform, which looks at proteins to determine treatment.
New Study Combines Checkpoint Inhibitors with Radiation Therapy to Boost Immune Response
Dr. Theodore Hong combines checkpoint inhibitors–a type of immunotherapy–with radiation to boost the immune system in pancreatic cancer treatment.
Tackling KRAS G12D
Dr. Leon Pappas explains the workings of the new KRAS G12D inhibitor, now in phase I/II clinical trials around the US and Australia.
Potential Therapy Takes a Two-Prong Attack on Pancreatic Cancer
With a focus on targeting cell metabolism, Dr. Anup Kasi leads a clinical trial of a new agent in combination with gemcitabine.
Claudin May Be the Next Big Target in Pancreatic Cancer Treatment
Dr. Wungki Park leads a trial that uses a monoclonal antibody to target a protein that is common in pancreatic cancer.
Finding More Targets for Pancreatic Cancer Treatment
Dr. Noelle LoConte discusses a clinical trial for cancer patients, including pancreatic cancer patients, that have an NRG1 gene fusion.
Triple Immunotherapy Shows Dramatic Results
Dr. William Freed-Pastor is testing a combination of three types of immunotherapy to attack pancreatic tumors.
Enhancing Standard Chemotherapy in Metastatic Pancreatic Cancer
Researchers are testing a new kinase inhibitor as a way to make standard chemotherapy more effective against advanced pancreatic cancer.
Overcoming Challenges to Vaccine Immunotherapy
Dr. Elizabeth Jaffee explains the challenges facing the scientists developing vaccine-based immunotherapy for pancreatic cancer.
Cachexia Research Showing Promise
Dr. Teresa Zimmers reports on the latest developments in countering cachexia in pancreatic cancer patients.
PanCAN 2021 Annual Scientific Summit
Pancreatic Cancer Action Network (PanCAN) held its annual scientific summit for an overview of the latest research projects they are funding.
Targeting the Undruggable KRAS Protein
Dr. Shubham Pant is focusing his research on effective treatments for the KRAS mutation, found in 90% of pancreatic cancers.
The Promise of Organoids
Dr. Brian Wolpin explains how organoids are being used to develop personalized treatment for pancreatic cancer patients.
Testing an Approved Drug for a Specific Mutation
Researchers are testing a drug combination for melanoma in pancreatic cancer patients with a BRAF genetic mutation.